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This paper described the studies on the mechanism of subcellular distribution of lipophilic weak bases. Although
the tissue distribution of basic drugs appeared to decrease with time simply in parallel with their plasma concentration,
their subcellular distribution in various tissues exhibited a variety of patterns. Basic drugs were distributed widely in
various tissues, but were concentrated in lung granule fraction, where their accumulation was dependent on their
lipophilicity and lysosomal uptake. As the plasma concentration of drugs decreased after maximum level, the contribu-
tion of lysosomes to their subcellular distribution increased. The uptake of the basic drugs into lysosomes depended both
on their intralysosomal pH and on the drug lipophilicity. As the lipophilicity of the basic drugs increased, they accumu-
lated more than the values predicted from the pH-partition theory and raised the intralysosomal pH more potently,
probably owing to their binding with lysosomal membranes with or without additional intralysosomal aggregation.
These phenomena should be considered as a basis of drug interaction in clinical treatments.





































Fig. 1. Diagrammatic Representation of Lysosomal Accumu-
lation of Basic Drugs through Protonation, Aggregation and
Binding to Membranes
B and BH＋ denote neutral and protonated species of a basic drug,
respectively, and D2＋ denotes dimmer of BH＋.
Table 1. Physicochemical Properties of Basic Drugs




















a) Values were obtained from Refs. 9 and 30.
b) Logarithm of the octanol-water partition coe‹cient of the nonionized









類以上の加水分解酵素を含み pH 3―6 の弱酸性，











まず，筆者らは，Lys阻害剤である NH4Cl (3 mg
/min/kg）をラットに定速静注し，Table 1 に示し
た塩基性薬物のうち Poct 値が中程度の biperiden
(BP）あるいは trihexyphenidyl (TP）を 2時間後か
ら併用して定速静注し，各組織―血漿中薬物濃度比
（Kp）を求めた．Table 2 には，コントロールある
いは NH4Cl投与群での BP及び TPの各 Kp値及び
NH4Cl による低下比を示した．25) NH4Cl 投与によ
































Lung 52.1±9.7 11.8±2.2 0.773 59.5±2.6 18.9±7.7 0.682
Heart 6.9±2.3 3.2±0.1 0.534 7.3±1.0 3.4±0.7 0.543
Kidney 8.7±1.5 4.1±0.2 0.526 13.5±1.1 7.0±1.1 0.484
Brain 6.6±1.5 3.8±0.1 0.432 6.8±0.7 4.5±0.7 0.332
Gut 9.8±2.2 7.0±0.5 0.286 15.0±3.3 8.6±0.7 0.425
Muscle 3.4±0.7 2.6±0.1 0.232 3.2±0.5 2.3±0.6 0.277
Fat 51.0±6.6 41.5±2.9 0.186 67.8±6.5 47.2±15.0 0.303
Each value represents the mean±S.D. of three rats. Asterisks denoto signiˆcant diŠerences (p＜0.05;p＜0.01). a) Kp after infusion of
biperiden or trihexyphenidyl alone. b) Kp after infusion of biperiden or trihexyphenidyl with NH4Cl. c) The values are the ratio of decrease
of Kp by NH4Cl.
Fig. 2. The Relationships between the Protein Content and Subcellular Fraction-to-Plasma Concentration Ratio (Kp, sf) of Biperiden
at Steady-State without NH4Cl Treatment (a) and the Relationships between the Speciˆc Activity of Acid Phosphatase and the
Decrease in the Ratio of the Kp, sf with NH4Cl Treatment (b) in Rat Lung.
The solid line represents the linear regression. P1: nuclear fraction, P2: post-nuclear fraction (e.g. lysosome, mitochondria), P3: microsome fraction, S1: cytosol
fraction. Mean ±S.E.M. (n＝3).
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ため，Lysと Mitを分離精製し in vitro結合実験を
行った．29) Figure 4 には，37°C における Lys 及び
Mit 画分への IMP の取り込みを Scatchard plotで
hon p.4 [100%]
560
Fig. 3. Subcellular Distribution of Chlorpromazine (CPZ),
Imipramine (IMP) and Biperiden (BP) in Rat Liver
Rats were injected i.v. with 3.2 mg/kg of each basic drug 10 min before
sacriˆce and their livers were fractionated. P1: nuclei fractions, Mit:
mitochondria, Lys: lysosome, P3: microsome, Sup: cytosol fractions. ……:
CPZ, ――: IMP, : BP.
Table 3. Dissociation Constants (Kd) and Maximum Number of Binding Sites (Bmax) Calculated from
Scatchard Analysis of Imipramine Uptake into Lysosome and Mitochondrial Fractions in the Absence
and Presence of NH4CI or Chlorpromazine (CPZ)










control 0.897±0.241 4.902±0.971 258±39 804±97
NH4Cl(50 mM) ― ― 237±50 603±112
CPZ(50 mM) ― ― 382±78 713±132
Mitochondria
control ― ― 421±129 832±241
NH4Cl(50 mM) ― ― 393±69 733±118
Each value represents the means ± S.D.of three to six experiments.
Fig. 4. Scatchard Plots of IMP Uptake into Lys and Mit
Fractions
Lys and Mit fractions were incubated at 37°C for 10 min with IMP in the



















臨床上，IMP の有効血漿中濃度は 100―300 ng/
mLとされており，肝臓の組織―血漿中薬物濃度比
（7.5）及び組織中蛋白量（18％）を用いて算出する








Fig. 5. EŠects of Nigericin (NIG), ATP and Baˆlomycin A1 (BAF) on [3H]IMP Uptake into Lys at pH 7.4 in KCl Medium
Lys fractions were preincubated at 37°C (a) or 4°C (b) for 3 min with NIG (2.5 mM), ATP (1 mM) and/or BAF (10 nM) before addition of [3H]IMP (1 mM).
○: control, ●: ＋NIG, △: ＋ATP, ▲: ＋ATP＋BAF.
Mean ±S.E.M. (n＝3).
Fig. 6. EŠect of the Medium Concentration of the Weakly
Basic Drugs on the Intralysosomal pH
▲: Chlorpromazine (CPZ), △: imipramine (IMP); ○: propranolol
(PPR), ●: NH4Cl. The dotted line (・・), the broken lines (), and
the solid lines show simulation curves for NH4Cl using Eq. 2; for CPZ, IMP,
and PPR using Eq. 3 for binding, and for CPZ, IMP, and PPR using Eq. 4
for aggregation, all obtained by means of the MULTI program.
No. 7




















5）．この ATP の効果は，baˆlomycin A1 を添加す
ることによってコントロールレベルに低下した．ま
た，nigericin によって取り込みは完全に阻害され
た．一方，4°C では，［ 3H]IMP の取り込みは，





を検討した結果，NH4Cl, IMP, propranolol (PPR）
及び CPZのいずれの場合も，薬物濃度の上昇に伴
って Lys 内 pH は上昇した（Fig. 6）．しかし，そ
の効果には薬物間で差があり，CPZが最も低濃度
で Lys内 pHを上昇させ，次いで IMP, PPR，NH4Cl
の順であった．［ 3H]IMP 及び［14C]methylamine
（［14C]MeNH2）の Lysへの取り込み阻害効果も pH
上昇作用と同様に CPZ が最も強く，次いで PPR,




Fig. 7. Inhibition of Uptake into Lys of [3H]IMP (Open Symbols) and [14C]MeNH2 (Closed Symbols) by Various Drugs at pH 7.4
at 4°C
The Lys fractions were incubated in the presence of CPZ, PPR or NH4Cl (1 mM-100 mM) at 4°C for 10 min, then [3H]IMP (1 nM) or [14C]MeNH2 was added.
After an additional 10 min incubation for [3H]IMP or 1 hr incubation for [14C]MeNH2 at 4°C, the [3H]IMP or [14C]MeNH2 taken up by Lys was determined.
CPZ or PPR (◯) and NH4Cl (△).
The dotted lines (・・) show simulation curves predicted for the inhibition of uptake of [3H]IMP or [14C]MeNH2 into Lys by NH4Cl using Eq. 5. The dotted
lines () show simulation curves predicted for the inhibition of uptake of [3H]IMP or [14C]MeNH2 into Lys by CPZ or PPR using Eq. 6 for binding. The solid
lines show simulation curves predicted for the inhibition of uptake of [3H]IMP or [14C]MeNH2 into Lys by CPZ or PPR using Eq. 7 for aggregation.
Fig. 8. The Relationship between the IC50 for [3H]IMP Up-
take and the Log Poct for Basic Drugs
The continuous line is the regression line for IC50 and log Poct. Chloro-













された（Fig. 8）．Lys への取り込みは medium pH
の上昇すなわちプロトン勾配の上昇に伴って増加し，
IMP の取り込みは Lys 内外の pH 差に依存するこ
とがわかった（Fig. 9）．De Duve らは既に塩基性
薬物の Lysへの取り込みが pH差に依存し，その濃






















Fig. 9. EŠect of Extralysosomal pH on the Accumulation of
[3H]IMP (1 mM) within Lysosomes




















場合，緩衝液の pH が 7.4 で薬物未添加の Lys 内
pHが Nの時，添加した塩基性薬物の濃度（x）と







される H＋ の量が Lys 内に生ずる遊離型の H＋ 付
加塩基の量に等しい薬物として NH4Clで検討した．
Figure 6 に示した NH4Cl の添加濃度と Lys 内 pH
の実測値との関係に式 2を適用し，MULTIプログ
ラムを用いた最小二乗法により，Lysの緩衝能（ b:


















用いて，Fig. 6に示す CPZあるいは PPRの薬物濃



















より Lys内 pHが yとなったときの取り込み量の比
で表せるため，xと yとの関係式より競合阻害効果



















1＋4 ･ K2･ b ･(－log Z)－1











Fig. 10. EŠect of the Medium Concentration on the In-
tralysosomal Accumulation of IMP
The open circles were the observed values of the accumulation ratio (in-
tralysosomal/extralysosomal concentration) of IMP at various ex-
tralysosomal concentrations after 10 min at 4°C. The dotted line was calcu-
lated using Eq. 8 for binding. The solid line was calculated using Eq. 9 for
aggregation.
Fig. 11. A Proposed Mechanism of Tissue Distribution of Basic Drugs
Vol. 121 (2001)
次に，IMP の添加濃度と Lys への濃縮比との関
係式を導いた．結合あるいは凝集の考慮により，そ
れぞれ次式が導かれる．
F′＝(1＋K1 ･ k ･ A)･ F 式 8
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